BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair

BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair

CDK4/6 inhibitors have shown clinical benefits in hormone receptor positive breast cancer. However, monotonous indications and unclear resistance mechanisms greatly limit the clinical application of these inhibitors. We attempt to improve the therapeutic effect of CDK4/6 inhibitors against breast ca...

Full description

Bibliographic Details
Main Authors:	Shuaishuai Chi, Fan Wei, Yangsha Li, Lei Yu, Chuyao Ma, Yanfen Fang, Biyu Yang, Yi Chen, Jian Ding
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Translational Oncology
Subjects:	CDK4 BRD4 Breast cancer Protein stability DNA damage
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324003395

Similar Items

Targeting Super‐Enhancers via Nanoparticle‐Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma
by: Chen‐Song Huang, et al.
Published: (2020-04-01)

Co-overexpression of BRD4 and CDK7 promotes cell proliferation and predicts poor prognosis in HCC
by: Xinxiu Li, et al.
Published: (2024-01-01)

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma
by: Mei Feng, et al.
Published: (2023-02-01)

Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism
by: Huasong Lu, et al.
Published: (2015-06-01)

Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis
by: Zhangxu He, et al.
Published: (2022-01-01)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
by: Adam P. Cribbs, et al.
Published: (2021-02-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning
by: Jian Wang, et al.
Published: (2024-04-01)

BRD4: an effective target for organ fibrosis
by: Qun Wei, et al.
Published: (2024-08-01)

PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer
by: Xin Jin, et al.
Published: (2019-11-01)

RSV Reprograms the CDK9•BRD4 Chromatin Remodeling Complex to Couple Innate Inflammation to Airway Remodeling
by: Allan R. Brasier
Published: (2020-04-01)

MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma
by: Gen Li, et al.
Published: (2024-02-01)

Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
by: Jonathan W. Riess, et al.
Published: (2021-10-01)

Design, synthesis, and evaluation of 4-(3-(3,5-dimethylisoxazol-4-yl)benzyl)phthalazin-1(2H)-one derivatives: potent BRD4 inhibitors with anti-breast cancer activity
by: Yingpeng Li, et al.
Published: (2023-11-01)

AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells
by: Cho-Hao Lin, et al.
Published: (2022-03-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

Synthesis and Structure–Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research
by: Minjin Yoo, et al.
Published: (2021-03-01)

Impact of bromodomain‐containing protein 4 (BRD4) and intestine‐specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity
by: Kai‐Ting Chuang, et al.
Published: (2021-08-01)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
by: Yilan Yang, et al.
Published: (2020-09-01)

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
by: ZHANG Baihong, et al.
Published: (2019-01-01)

Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
by: Zhimin Zhang, et al.
Published: (2019-01-01)

Bromodomain Containing Protein 4 (BRD4) Regulates Expression of its Interacting Coactivators in the Innate Response to Respiratory Syncytial Virus
by: Xiaofang Xu, et al.
Published: (2021-10-01)

JQ1 as a BRD4 Inhibitor Blocks Inflammatory Pyroptosis-Related Acute Colon Injury Induced by LPS
by: Ling Chen, et al.
Published: (2021-02-01)

Inhibition of BRD4 Promotes Pexophagy by Increasing ROS and ATM Activation
by: Yong Hwan Kim, et al.
Published: (2022-09-01)

Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells
by: Chang Liu, et al.
Published: (2021-09-01)

Recent Progress in CDK4/6 Inhibitors and PROTACs
by: Hao Wang, et al.
Published: (2023-12-01)

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma
by: Elana Thieme, et al.
Published: (2023-03-01)

Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion
by: Felipe Andreiuolo, et al.
Published: (2024-03-01)

Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure
by: Edrous Alamer, et al.
Published: (2021-01-01)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
by: Ran Sun, et al.
Published: (2022-04-01)

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer
by: Huaiyuan Liang, et al.
Published: (2023-12-01)

N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
by: Joshua A. Nord, et al.
Published: (2022-09-01)

The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
by: Yingxin Pang, et al.
Published: (2022-07-01)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway
by: Li H, et al.
Published: (2022-01-01)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
by: Noemi Martella, et al.
Published: (2023-03-01)

A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association
by: Huachao Huang, et al.
Published: (2017-06-01)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01)

BRD4 sustains p63 transcriptional program in keratinocytes
by: E. Foffi, et al.
Published: (2024-11-01)

Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma
by: Xinchao Wu, et al.
Published: (2017-04-01)